GSK secures rights to Syndivia’s ADC asset for prostate cancer
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
TCT 2025: ShortCUT Trial Compares Cutting Balloon Angioplasty and Intravascular Lithotripsy (IVL) for Calcified Coronary Artery Disease Th…
Motsoaledi Relaunches Parliamentary TB Caucus Health Minister Aaron Motsoaledi announced that the country is entering a new era of account…
TCT 2025: TRILUMINATE Pivotal Trial Results The Medical Dialogues Bureau at the TCT Conference 2025 in San Francisco, USA, reports on the …
SELUTION DeNovo Trial Results The SELUTION DeNovo randomized clinical trial, presented at TCT 2025 in San Francisco, USA, demonstrated non…
EVOQUE Transcatheter Tricuspid Valve Replacement Demonstrates Favorable Outcomes The EVOQUE system has shown promising results in real-wor…
Cygnet Energy Enters into Agreement to Acquire Kiwetinohk Energy Corp. Cygnet Energy Ltd., a private exploration and production com…
Grokipedia Launch and Controversy Elon Musk's Grokipedia, a rival to Wikipedia, launched after a brief crash, sparking controversy over it…